University of Queensland produces life saving early warning diagnostics using Evolution gold

Location

All sites

Site

Group

Impact Area

Community Engagement

Purpose

The main uses of gold include jewellery, coinage, investment, dentistry, medicine, mobile phones, computers and laptops. Since 2019, Evolution has been making a difference by supporting innovative uses of gold for medical research. We committed $1 million over three years to support the University of Queensland’s Australian Institute of Bioengineering and Nanotechnology to develop the Immunostorm chip – a novel diagnostic device with gold nanoparticles that tests blood to rapidly detect cancer cells in the human body. This chip has the potential to enable early diagnosis for all cancer types and improve survival rates.

The research scope was expanded following the emergence of COVID-19, leveraging the gold nanoparticle technology in the Immuno-Storm to detect warning signs of cytokine storms, and uncontrolled release of cytokines which can result in hyperinflammation and tissue damage in some cancer and COVID-19 patients.

The outcomes of this Shared Value Project have exceeded expectations and demonstrated further applicability and accessibility of gold-based products in medicine in diagnosing long-term impacts of these chronic diseases, as well as applicability in the areas of:
• Psychology
• Auto-immune diseases
• Neurology
• Aging
Evolution and UQ look forward to strengthening our relationship in the hope of pursuing successes that have long-lasting and transformative benefits to our communities.

Scroll to Top

Disclaimer

Please note that you are now entering a website directly or indirectly maintained by a third party (the “External Site”) and that you do so at your own risk.

Evolution Mining LTD., (“EVN”) has no control over the External Site, any data or other content contained therein or any additional linked websites. The link to the External Site is provided for convenience purposes only.

By clicking “Accept” you acknowledge and agree that neither EVN nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against EVN and Virtua and further acknowledge and agree that in no event shall EVN or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if EVN and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-IFRS Information

In addition to disclosing results determined in accordance with IFRS, EVN may also disclose certain non-IFRS and pro forma non-IFRS results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-IFRS and pro forma non-IFRS information provides investors with additional information to assess EVN operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-IFRS and pro forma non-IFRS information, along with IFRS information, in evaluating its historical operating performance. EVN and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-IFRS information is not prepared in accordance with IFRS and may not be comparable to non-IFRS information used by other companies. The non-IFRS information should not be viewed as a substitute for, or superior to, other data prepared in accordance with IFRS.